155 related articles for article (PubMed ID: 15117333)
1. Restoration of immunity and reactivation of hepatitis B virus after immunosuppressive therapy in a patient with severe aplastic anaemia.
Dai MS; Kao WY; Shyu RY; Chao TY
J Viral Hepat; 2004 May; 11(3):283-5. PubMed ID: 15117333
[TBL] [Abstract][Full Text] [Related]
2. [Immunotherapy in aplastic anaemia as a cause of reactivation of hepatitis B virus-immunologic aspects].
Luczyński W; Muszyńska-Rosłan K; Krawczuk-Rybak M; Lebensztejn DM
Wiad Lek; 2005; 58(11-12):697-9. PubMed ID: 16594488
[TBL] [Abstract][Full Text] [Related]
3. Epstein-Barr virus reactivation in a patient treated with anti-thymocyte globulin for severe aplastic anemia.
Calistri E; Tiribelli M; Battista M; Michelutti A; Corbellino M; Viale P; Fanin R; Damiani D
Am J Hematol; 2006 May; 81(5):355-7. PubMed ID: 16628717
[TBL] [Abstract][Full Text] [Related]
4. Quantitative detection of hepatitis B surface antigen by chemiluminescent microparticle immunoassay during lamivudine treatment of chronic hepatitis B virus carriers.
Kohmoto M; Enomoto M; Tamori A; Habu D; Takeda T; Kawada N; Sakaguchi H; Seki S; Shiomi S; Nishiguchi S
J Med Virol; 2005 Feb; 75(2):235-9. PubMed ID: 15602726
[TBL] [Abstract][Full Text] [Related]
5. A 3-year clinical trial of lamivudine in treatment of patients with chronic hepatitis B.
Yao GB; Cui ZY; Wang BE; Yao JL; Zeng MD
Hepatobiliary Pancreat Dis Int; 2004 May; 3(2):188-93. PubMed ID: 15138107
[TBL] [Abstract][Full Text] [Related]
6. Clinical outcomes of chronic hepatitis B patients with persistently detectable serum hepatitis B virus DNA during lamivudine therapy.
Kim JH; Yu SK; Seo YS; Yim HJ; Yeon JE; Park JJ; Kim JS; Bak YT; Lee CH; Byun KS
J Gastroenterol Hepatol; 2007 Aug; 22(8):1220-5. PubMed ID: 17532786
[TBL] [Abstract][Full Text] [Related]
7. Effect of long-term lamivudine in chronic hepatitis B virus-infected children.
Ozgenç F; Arikan C; Sertoz RY; Nart D; Aydogdu S; Yagci RV
Antivir Ther; 2004 Oct; 9(5):729-32. PubMed ID: 15535410
[TBL] [Abstract][Full Text] [Related]
8. Selection of precore mutants during lamivudine treatment in patients with chronic hepatitis B.
Cheong JY; Cho SW; Yoo JH; Hong SP; Kim SO; Yoo WD; Kim JH
Hepatogastroenterology; 2008; 55(84):1029-33. PubMed ID: 18705323
[TBL] [Abstract][Full Text] [Related]
9. Diagnosis and treatment of chronic hepatitis B: an update.
Morgan M; Park W; Keeffe EB
Minerva Gastroenterol Dietol; 2007 Mar; 53(1):25-41. PubMed ID: 17415343
[TBL] [Abstract][Full Text] [Related]
10. Outcome of anti-thymocyte immunoglobulin plus cyclosporine A for severe aplastic anaemia with chronic hepatitis B virus infection.
Chen M; Zhuang J; Zhou D; Xu Y; Zhao Y; Wang S; Zhang W; Duan M; Zhu T; Li J; Cai H; Cao X; Han B
Ann Hematol; 2017 Apr; 96(4):581-587. PubMed ID: 28084534
[TBL] [Abstract][Full Text] [Related]
11. A three-month course of lamivudine therapy in HBeAg-positive hepatitis B patients with normal aminotransferase levels.
Yalçin K; Değertekin H; Kokoğlu OF; Ayaz C
Turk J Gastroenterol; 2004 Mar; 15(1):14-20. PubMed ID: 15264116
[TBL] [Abstract][Full Text] [Related]
12. A 7-year study of lamivudine therapy for hepatitis B virus e antigen-positive chronic hepatitis B patients in China.
Yao GB; Zhu M; Cui ZY; Wang BE; Yao JL; Zeng MD
J Dig Dis; 2009 May; 10(2):131-7. PubMed ID: 19426396
[TBL] [Abstract][Full Text] [Related]
13. Impact of highly active antiretroviral therapy (HAART) on the natural history of hepatitis B virus (HBV) and HIV coinfection: relationship between prolonged efficacy of HAART and HBV surface and early antigen seroconversion.
Miailhes P; Trabaud MA; Pradat P; Lebouché B; Chevallier M; Chevallier P; Zoulim F; Trepo C
Clin Infect Dis; 2007 Sep; 45(5):624-32. PubMed ID: 17682999
[TBL] [Abstract][Full Text] [Related]
14. Delayed hepatitis B virus reactivation after cessation of preemptive lamivudine in lymphoma patients treated with rituximab plus CHOP.
Dai MS; Chao TY; Kao WY; Shyu RY; Liu TM
Ann Hematol; 2004 Dec; 83(12):769-74. PubMed ID: 15338194
[TBL] [Abstract][Full Text] [Related]
15. [Durability of HBeAg seroconversion in lamivudine treatment of chronic hepatitis B patients].
Zhu M; Xu B; Yao GB
Zhonghua Gan Zang Bing Za Zhi; 2005 Jul; 13(7):534-6. PubMed ID: 16042894
[TBL] [Abstract][Full Text] [Related]
16. Genotype prevalence, viral load and outcome of hepatitis B virus precore mutant infection in stable patients and in patients after liver transplantation.
Ben-Ari Z; Ashur Y; Daudi N; Shmilovitz-Wiess H; Brown M; Sulkes J; Klein A; Mor E; Tur-Kaspa R; Shouval D
Clin Transplant; 2004 Aug; 18(4):415-22. PubMed ID: 15233819
[TBL] [Abstract][Full Text] [Related]
17. Response to long-term lamivudine treatment (up to 5 years) in patients with severe chronic hepatitis B, role of genotype and drug resistance.
Moskovitz DN; Osiowy C; Giles E; Tomlinson G; Heathcote EJ
J Viral Hepat; 2005 Jul; 12(4):398-404. PubMed ID: 15985011
[TBL] [Abstract][Full Text] [Related]
18. Role of long-term lamivudine treatment of hepatitis B virus recurrence after liver transplantation.
Woo HY; Choi JY; Jang JW; You CR; Bae SH; Yoon SK; Yang JM; Choi SW; Han NI; Kim DG
J Med Virol; 2008 Nov; 80(11):1891-9. PubMed ID: 18814257
[TBL] [Abstract][Full Text] [Related]
19. Chronic hepatitis B reactivation following infliximab therapy in Crohn's disease patients: need for primary prophylaxis.
Esteve M; Saro C; González-Huix F; Suarez F; Forné M; Viver JM
Gut; 2004 Sep; 53(9):1363-5. PubMed ID: 15306601
[TBL] [Abstract][Full Text] [Related]
20. Diagnosis and treatment of chronic hepatitis B: 2009 update.
Morgan M; Keeffe EB
Minerva Gastroenterol Dietol; 2009 Mar; 55(1):5-22. PubMed ID: 19212304
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
